Menu
Novo Nordisk, Merck and GSK announced they will refund covered entities following certain overcharges for 340B drugs.

Novo Nordisk, Merck, GSK to Refund 340B Covered Entities for Overcharges

Bella Czajkowski, National Correspondent 340B Report Views
Three drugmakers will refund covered entities that purchased certain 340B-priced medications following recent adjustments to their 340B drug ceiling prices. [...]

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.

Post Navigation

Column: Battlefront Shifts from Contract Pharmacies to Rebates

State Contract Pharmacy Lawsuit Roundup: Health Center Group Motion Denied in 5th Circuit; Drug Industry Makes Motion in Federal Court in South Dakota 

Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Quick verification required before signup

Site Footer Live